Denifanstat / Resmetirom Combination
MASH
Phase 2Exploratory
Key Facts
About Sagimet Biosciences
Sagimet Biosciences is advancing a novel therapeutic platform centered on the selective inhibition of Fatty Acid Synthase (FASN), a key enzyme in the dysfunctional de novo lipogenesis pathway. The company's lead asset, denifanstat, has achieved critical milestones, including positive Phase 2b biopsy data in MASH (FASCINATE-2), Breakthrough Therapy designation from the FDA, and successful Phase 3 results in acne from a partner-led trial. With a seasoned leadership team and a clear path to Phase 3 in MASH, Sagimet's strategy is to develop first-in-class oral therapies for diseases driven by lipotoxicity, including MASH, acne, and select cancers.
View full company profileTherapeutic Areas
Other MASH Drugs
| Drug | Company | Phase |
|---|---|---|
| Leronlimab | CytoDyn | Phase 2 |
| Metabolic dysfunction-associated steatohepatitis (siRNA) | GeneToBe | Discovery |
| Metabolic Disease Program | Kriya Therapeutics | Unknown |
| siRNA (SLC25A5/ANT2 target) | Novo Nordisk | Phase 1 |